Erlotinib
|
|
|
- CAS-Nr.
- 183321-74-6
- Englisch Name:
- Erlotinib
- Synonyma:
- ERLOTINIB HCL;Tarceva;Erlortinib;R 1415;Rotini;OSI 744;Erlonat;ERLOTININ;ERLOTINIB;NSC-71878
- CBNumber:
- CB9285914
- Summenformel:
- C22H23N3O4
- Molgewicht:
- 393.44
- MOL-Datei:
- 183321-74-6.mol
|
Erlotinib Eigenschaften
- Schmelzpunkt:
- 159-160 °C
- Siedepunkt:
- 553.6±50.0 °C(Predicted)
- Dichte
- 1.24
- storage temp.
- Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- L?slichkeit
- Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 5.32±0.30(Predicted)
- Farbe
- White
- InChI
- InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
- InChIKey
- AAKJLRGGTJKAMG-UHFFFAOYSA-N
- SMILES
- N1=C2C(C=C(OCCOC)C(OCCOC)=C2)=C(NC2=CC=CC(C#C)=C2)N=C1
- CAS Datenbank
- 183321-74-6(CAS DataBase Reference)
Erlotinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-
associated kinase activity (IC
50 = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED
50 value of 9 mg/kg. Erlotinib also suppresses cyclin-
dependent kinase 2 (Cdk2) activity in breast cancer cells (IC
50 = 4.6 μM) and JAK2 mutant JAK2
V617F positive hematopoietic progenitor cells (IC
50 = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.
Verwenden
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.
Definition
ChEBI: A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.
Allgemeine Beschreibung
Class: receptor tyrosine kinase
Treatment: NSCLC
Oral bioavailability = 60%
Elimination half-life = 36 h
Protein binding = 93%
Nebenwirkungen
- Burning, tingling, numbness or pain in the hands, arms, feet, or legs.
- cough or hoarseness.
- diarrhea (severe)
- difficult or labored breathing.
- fever or chills.
- rash (severe)
- sensation of pins and needles.
- stabbing chest pain.
Erlotinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Erlotinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 473)Lieferanten
183321-74-6()Verwandte Suche:
- ERLOTINIB
- ERLOTINIB HCL SALT
- 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
- n-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine
- Erlotinib Hydrochloirde
- 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-
- ERLOTININ
- N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
- Erlotinib & its intermediates
- CP-358774, Ro 50-8231
- Erlotinib Free Base
- OSI 744
- R 1415
- Erlotinib &aMp
- its interMediates
- O-desmethyl erlotinib carboxylic acid
- Erlotinib N-(3-Ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine
- Erlotinib ERLOTINIB
- Erlotinib (OSI-744)
- Erlonat
- Erlotinib (Tarceva)
- NSC-71878
- OSI744;CP-358774;NSC-71878;ERLOTINIB HCL (OSI 744;CP358774;NSC718781)
- Erlotinib USP/EP/BP
- Erlotinib (OSI744, Tarceva)
- ErlotinibQ: What is
Erlotinib Q: What is the CAS Number of
Erlotinib Q: What is the storage condition of
Erlotinib Q: What are the applications of
Erlotinib
- Erlotinib 183321-74-6
- Rotini
- R-1415CP-358,774
- Erlotinib (OSI-774)
- Noradrenaline Impurity 26
- Erlotinib, 10 mM in DMSO
- Erlotinib (NSC-718781
- Erlotinib hydrochloride CRS
- ERLOTINIB HCL
- Erlortinib
- Tarceva
- 183321-74-6
- 83321-74-6
- 68304-21-3
- 2139253-68-1
- Isotope
- Anti-cancer&immunity
- Antineoplastic
- Inhibitors
- API
- APIs
- Pharmaceutical intermediate
- Erlotinib
- Tarceva
